scholarly journals FlowCell-enriched circulating tumor cells as a predictor of lung cancer metastasis

Human Cell ◽  
2021 ◽  
Author(s):  
Yan Lu ◽  
Yushuang Zheng ◽  
Yuhong Wang ◽  
Dongmei Gu ◽  
Jun Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cancer Metastasis ◽  
Lung Tumor ◽  
Early Stage ◽  
High Rate ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Metastasis ◽  
Number Of Patients

AbstractLung cancer is the most fetal malignancy due to the high rate of metastasis and recurrence after treatment. A considerable number of patients with early-stage lung cancer relapse due to overlooked distant metastasis. Circulating tumor cells (CTCs) are tumor cells in blood circulation that originated from primary or metastatic sites, and it has been shown that CTCs are critical for metastasis and prognosis in various type of cancers. Here, we employed novel method to capture, isolate and classify CTC with FlowCell system and analyzed the CTCs from a cohort of 302 individuals. Our results illustrated that FlowCell-enriched CTCs effectively differentiated benign and malignant lung tumor and the total CTC counts increased as the tumor developed. More importantly, we showed that CTCs displayed superior sensitivity and specificity to predict lung cancer metastasis in comparison to conventional circulating biomarkers. Taken together, our data suggested CTCs can be used to assist the diagnosis of lung cancer as well as predict lung cancer metastasis. These findings provide an alternative means to screen early-stage metastasis.

scholarly journals Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer

2016 ◽  
Vol 151 (3) ◽  
pp. 852-858 ◽  
Author(s):  
Rishindra M. Reddy ◽  
Vasudha Murlidhar ◽  
Lili Zhao ◽  
Svetlana Grabauskiene ◽  
Zhuo Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Stage ◽  
Venous Blood ◽  
Blood Sampling ◽  
Early Stage Lung Cancer ◽  
Venous Blood Sampling ◽  
Stage Lung Cancer

scholarly journals Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal

2020 ◽  
Author(s):  
Dawei Yang ◽  
Xiaofang Yang ◽  
Yang Li ◽  
Peige Zhao ◽  
Rao Fu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Stage ◽  
Effective Means ◽  
Disease Recurrence ◽  
Metabolic Changes ◽  
Surgical Removal ◽  
Targeted Metabolomics ◽  
Post Surgery

Abstract Background Lung cancer (LC) remains the deadliest form of cancer globally. While surgery remains the optimal treatment strategy for individuals with early-stage LC, what the metabolic consequences are of such surgical intervention remains uncertain. Methods Negative enrichment-fluorescence in situ hybridization (NE-FISH) was used in an effort to detect circulating tumor cells (CTCs) in pre- and post-surgery peripheral blood samples from 51 LC patients. In addition, targeted metabolomics analyses, multivariate statistical analyses, and pathway analyses were used to explore surgery-associated metabolic changes. Results LC patients had significantly higher CTC counts relative to healthy controls with 66.67% of LC patients having at least 1 detected CTC. CTC counts were associated with clinical outcomes following surgery. In a targeted metabolomics analysis, we detected 34 amino acids, 164 lipids, and 24 fatty acids. When comparing LC patients before and after surgery to control patients, metabolic shifts were detected via PLS-DA and pathway analysis. Further surgery-associated metabolic changes were identified when comparing LA and LB groups. We identified SM 42:4, Ser, Sar, Gln, and LPC 18:0 for inclusion in a biomarker panel for early-stage LC detection based upon an AUC of 0.965 (95% CI = 0.900–1.000). This analysis revealed that SM 42:2, SM 35:1, PC (16:0/14:0), PC (14:0/16:1), Cer (d18:1/24:1), and SM 38:3 may offer diagnostic and prognostic benefits in LC. Conclusions These findings suggest that CTC detection and plasma metabolite profiling may be an effective means of diagnosing early-stage LC and identifying patients at risk for disease recurrence.

scholarly journals Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes

2007 ◽  
Vol 13 (14) ◽  
pp. 4105-4110 ◽  
Author(s):  
Taku Nakagawa ◽  
Steve R. Martinez ◽  
Yasufumi Goto ◽  
Kazuo Koyanagi ◽  
Minoru Kitago ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cancer Metastasis ◽  
Early Stage ◽  
Breast Cancer Metastasis ◽  
Early Stage Breast Cancer ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph

scholarly journals Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal

2020 ◽  
Author(s):  
Dawei Yang ◽  
Xiaofang Yang ◽  
Yang Li ◽  
Peige Zhao ◽  
Rao Fu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Stage ◽  
Effective Means ◽  
Disease Recurrence ◽  
Metabolic Changes ◽  
Surgical Removal ◽  
Targeted Metabolomics ◽  
Post Surgery

Abstract Background: Lung cancer (LC) remains the deadliest form of cancer globally. While surgery remains the optimal treatment strategy for individuals with early-stage LC, what the metabolic consequences are of such surgical intervention remains uncertain. Methods: Negative enrichment-fluorescence in situ hybridization (NE-FISH) was used in an effort to detect circulating tumor cells (CTCs) in pre- and post-surgery peripheral blood samples from 51 LC patients. In addition, targeted metabolomics analyses, multivariate statistical analyses, and pathway analyses were used to explore surgery-associated metabolic changes. Results: LC patients had significantly higher CTC counts relative to healthy controls with 66.67% of LC patients having at least 1 detected CTC before surgery. CTC counts were associated with clinical outcomes following surgery. In a targeted metabolomics analysis, we detected 34 amino acids, 147 lipids, and 24 fatty acids. When comparing LC patients before and after surgery to control patients, metabolic shifts were detected via PLS-DA and pathway analysis. Further surgery-associated metabolic changes were identified when comparing LA (LC patients after surgery) and LB (LC patients before surgery) groups. We identified SM 42:4, Ser, Sar, Gln, and LPC 18:0 for inclusion in a biomarker panel for early-stage LC detection based upon an AUC of 0.965 (95% CI = 0.900–1.000). This analysis revealed that SM 42:2, SM 35:1, PC (16:0/14:0), PC (14:0/16:1), Cer (d18:1/24:1), and SM 38:3 may offer diagnostic and prognostic benefits in LC. Conclusions: These findings suggest that CTC detection and plasma metabolite profiling may be an effective means of diagnosing early-stage LC and identifying patients at risk for disease recurrence.

scholarly journals Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer

2020 ◽  
Vol Volume 13 ◽  
pp. 1931-1939 ◽  
Author(s):  
Guo-Chen Duan ◽  
Xiao-Peng Zhang ◽  
Hui-En Wang ◽  
Zhi-Kang Wang ◽  
Hua Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Diagnostic Marker ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

EP-1222 “SLOW” CT SCAN FOR INCORPORATING LUNG TUMOR MOBILITY IN RADIOTHERAPY PLANNING IN EARLY STAGE LUNG CANCER

2012 ◽  
Vol 103 ◽  
pp. S469
Author(s):  
M. Molla ◽  
A. Seoane ◽  
O. Coronil ◽  
C. Delgado ◽  
A. Campos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Ct Scan ◽  
Lung Tumor ◽  
Early Stage ◽  
Radiotherapy Planning ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

scholarly journals Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer

2021 ◽  
Author(s):  
Fraser R Millar ◽  
Adam Pennycuick ◽  
Morwenna Muir ◽  
Andrea Quintanilla ◽  
Priya Hari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Potential ◽  
Lung Tumor ◽  
Early Stage ◽  
Immune Surveillance ◽  
Genetically Engineered ◽  
Toll Like Receptor ◽  
Early Stage Lung Cancer ◽  
Toll Like Receptor 2 ◽  
Stage Lung Cancer

Targeting early-stage lung cancer is vital to improve overall survival. We previously identified Toll-like receptor 2 (TLR2) as a regulator of oncogene-induced senescence (OIS) and the senescence-associated secretory phenotype (SASP), both key for tumor suppression. Here, we demonstrate that TLR2 is widely expressed in human lung tumor epithelium where it correlates with improved survival and clinical regression. Using genetically engineered mouse models of lung cancer we have shown that Tlr2 is a tumor suppressor in lung cancer initiation via regulation of proliferation and the SASP. The SASP is integral in the regulation of immune surveillance of premalignant cells, and we observe impaired myeloid derived immune surveillance following Tlr2 loss. Lastly, we show that administration of a synthetic Tlr2 agonist significantly reduces preinvasive lung tumor growth. Our data highlight an unexpected tumor surveillance pathway in early-stage lung cancer with therapeutic potential.

Sign in / Sign up

Export Citation Format

Share Document